Novartis announces positive phase III results for MS drug siponimod

ZURICH, Aug 25 (Reuters) - Novartis AG said a

late-stage study showed its oral, once-daily BAF312, or

siponimod, reduced the risk of disability progression in a

severe form of multiple sclerosis.

Read more